Fundraising Fox
NĒRx BioSciences
Indianapolis, US · 2 known investors
Find your way into NĒRx BioSciences
Sign up to see every warm intro you have to NĒRx BioSciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NĒRx BioSciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NĒRx Biosciences develops small molecule inhibitors targeting DNA damage sensor proteins for cancer treatment, with initial focus on difficult-to-treat lung and ovarian cancers. The company builds on two decades of academic research from Indiana University's School of Medicine on DNA damage and repair mechanisms.
Founders & leadership
Investors · 2
How we know: funding news · elevateventures.com · the VCSheet dataset · Not right? Tell us
How we know: IU Ventures's portfolio page · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 2 of 3 rounds · 2018–2023
▶$200KraisedNov 2021 · 3 investors · BiotechnologyRule 506(b)
- John J. TurchiExecutive Officer, Director
- Katherine PawelczakExecutive Officer, Director
- Trent CarrierDirector
- Offering amount
- $400K
- Amount sold
- $200K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$850KraisedJan 2019 · 9 investors · BiotechnologyRule 506(b)
- Nicholas BallExecutive Officer, Director
- John J. TurchiExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $850K
- Minimum investment
- $25K
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $293K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $299.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $299.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2012 | $229.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does NĒRx BioSciences do?
- NĒRx Biosciences develops small molecule inhibitors targeting DNA damage sensor proteins for cancer treatment, with initial focus on difficult-to-treat lung and ovarian cancers. The company builds on two decades of academic research from Indiana University's School of Medicine on DNA damage and repair mechanisms.
- Who founded NĒRx BioSciences?
- NĒRx BioSciences was founded by John Turchi.
- Who are NĒRx BioSciences's investors?
- NĒRx BioSciences's investors include Elevate Ventures, IU Ventures.
- How much funding has NĒRx BioSciences raised?
- NĒRx BioSciences has disclosed $1.1M raised across 2 of its 3 known rounds.
- Where is NĒRx BioSciences headquartered?
- NĒRx BioSciences is headquartered in Indianapolis, US.